CNSP (CNS Pharmaceuticals) Change In Receivables : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CNS Pharmaceuticals Change In Receivables?

CNS Pharmaceuticals's change in receivables for the quarter that ended in Sep. 2024 was $0.00 Mil. It means CNS Pharmaceuticals's Accounts Receivable stayed the same from Jun. 2024 to Sep. 2024 .

CNS Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means CNS Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

CNS Pharmaceuticals's Accounts Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. CNS Pharmaceuticals's liquidation value for the three months ended in Sep. 2024 was $2.92 Mil.

CNS Pharmaceuticals Change In Receivables Historical Data

The historical data trend for CNS Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNS Pharmaceuticals Change In Receivables Chart

CNS Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

CNS Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

CNS Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

CNS Pharmaceuticals (NAS:CNSP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

CNS Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, CNS Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

CNS Pharmaceuticals's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	6.973	-	4.057	+	0.75 * 0	+	0.5 * 0
=	2.92

CNS Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of CNS Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

CNS Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNS Pharmaceuticals Inc (NAS:CNSP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

2100 West Loop South, Suite 900, Houston, TX, USA, 77027

Website

https://www.cnspharma.com

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Executives

Christopher Downs	officer: Chief Financial Officer	31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
John M Climaco	director, officer: Chief Executive Officer	PO BOX 326, PARK CITY UT 84060
Carl Anthony Evans	director	C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Jerzy Gumulka	director	C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Bettina M. Cockroft	director	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Waldemar Priebe	10 percent owner	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Jeffry R. Keyes	director	13950 STOWE DRIVE, POWAY CA 92064-8803
Andrzej Andraczke	director	C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027